Post-pan­dem­ic and flush with cash, Vir eyes new fron­tiers in on­col­o­gy and neu­rol­o­gy

Vir Biotech­nol­o­gy is best known for jump­ing in­to ac­tion dur­ing a cri­sis: It helped cre­ate an an­ti­body dur­ing the Ebo­la out­break and sprint­ed to make a Covid-19 treat­ment with GSK in the ear­li­est days of the pan­dem­ic.

But now, as its Covid sales dwin­dle, the US and Swiss biotech is on the hunt for ways to move in­to “oth­er vi­ral-as­so­ci­at­ed dis­eases, or any­where where im­mune tar­get­ing is im­por­tant, such as in on­col­o­gy and neu­rol­o­gy,” CEO Mar­i­anne De Backer told End­points News. “You will, in the fu­ture, see some ex­am­ples of that.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER